Pharmaceutical Research Overview
Zyloric 100 mg Glaxosmithkline is a pharmaceutical-grade allopurinol formulation manufactured by GlaxoSmithKline for laboratory research applications. Allopurinol belongs to the xanthine oxidase inhibitor class, representing a purine analogue that demonstrates specific enzyme inhibition properties in biochemical studies. This compound serves as a valuable research tool for investigating purine metabolism pathways, enzyme kinetics, and related biochemical mechanisms in controlled laboratory environments. Research scientists frequently examine this compound’s molecular interactions within metabolic research frameworks, particularly when studying xanthine oxidase enzyme function and purine catabolism processes.
The pharmaceutical preparation provides researchers with a standardised compound for evaluating xanthine oxidase inhibition mechanisms across various experimental models. Laboratory investigations commonly analyse this compound’s effects on uric acid formation pathways, enzyme binding characteristics, and metabolic modulation properties. Research applications extend to studying purine metabolism disorders, enzyme inhibition kinetics, and related biochemical pathways. Scientists at Stroid UK Shop frequently investigate such compounds alongside other research chemicals from our comprehensive catalogue, including specialized compounds available in our allopurinol research category.
Laboratory researchers often examine this compound in comparative studies with other metabolic modulators, including novel research chemicals available through our selective androgen receptor modulator collection and advanced compounds featured in our research peptide catalogue. The pharmaceutical-grade formulation ensures consistent research parameters when conducting controlled experiments examining xanthine oxidase inhibition mechanisms.
Research investigations commonly focus on this compound’s molecular binding properties, enzyme inhibition kinetics, and metabolic pathway modulation effects. Laboratory studies examine its role in purine metabolism regulation, uric acid synthesis inhibition, and related biochemical processes. The compound’s well-characterized pharmaceutical profile makes it suitable for comparative enzyme inhibition studies and metabolic research applications.
Research Applications
Laboratory investigations frequently examine Zyloric’s xanthine oxidase inhibition properties within controlled experimental frameworks. Research applications include studying enzyme kinetics, metabolic pathway modulation, and purine catabolism mechanisms. Scientists investigate this compound’s molecular interactions with xanthine oxidase enzymes, examining binding characteristics and inhibition parameters across various experimental conditions.
Biochemical research commonly evaluates this compound’s effects on uric acid formation pathways, enzyme specificity, and metabolic regulation mechanisms. Laboratory studies investigate its role in purine metabolism research, enzyme inhibition studies, and related biochemical pathway analyses. Research frameworks often incorporate this compound when examining metabolic disorders, enzyme function studies, and comparative inhibition research.
Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Allopurinol |
| Dosage | 100 mg per tablet |
| Manufacturer | GlaxoSmithKline |
| Formulation | Pharmaceutical tablet |
| CAS Number | 315-30-0 |
| Molecular Formula | C₅H₄N₄O |
| Molecular Weight | 136.11 g/mol |
| Storage | Room temperature, dry conditions |
Research Compliance
This product is manufactured for laboratory research purposes only and is not intended for human consumption, therapeutic use, or any non-research applications. Researchers must ensure compliance with applicable regulations and institutional guidelines when handling this compound. Proper laboratory protocols, safety measures, and disposal procedures must be observed during all research activities involving this product.
